key: cord-1017451-nbujk1cg
authors: Baiocchi, G. C.; Vojdani, A.; Rosenberg, A. Z.; Vojdani, E.; Halpert, G.; Ostrinski, Y.; Zyskind, I.; Filgueiras, I. S.; Schimke, L. F.; Marques, A. H. C.; Giil, L. M.; Lavi, Y. B.; Silverberg, J. I.; Zimmerman, J.; Hill, D. A.; Thornton, A.; Kim, M.; De Vito, R.; Fonseca, D. L. M.; Placa, D. R.; Freire, P. P.; Camara, N. O. S.; Calich, V. L. G.; Heidecke, H.; Lattin, M. T.; Ochs, H. D.; Riemekasten, G.; Amital, H.; Marques, O. C.; Shoenfeld, Y.
title: Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes
date: 2022-02-18
journal: nan
DOI: 10.1101/2022.02.17.22271057
sha: 48436558731172b3c1b69ed2dbd5bf5c3ab29f16
doc_id: 1017451
cord_uid: nbujk1cg

The SARS-CoV-2 infection is associated with increased levels of autoantibodies targeting immunological proteins such as cytokines and chemokines. Reports further indicate that COVID-19 patients may develop a wide spectrum of autoimmune diseases due to reasons not fully understood. Even so, the landscape of autoantibodies induced by SARS-CoV-2 infection remains uncharted territory. To gain more insight, we carried out a comprehensive assessment of autoantibodies known to be linked to diverse autoimmune diseases observed in COVID-19 patients, in a cohort of 248 individuals, of which 171 were COVID-19 patients (74 with mild, 65 moderate, and 32 with severe disease) and 77 were healthy controls. Dysregulated autoantibody serum levels, characterized mainly by elevated concentrations, occurred mostly in patients with moderate or severe COVID-19 infection, and was accompanied by a progressive disruption of physiologic IgG and IgA autoantibody signatures. A similar perturbation was found in patients with anosmia. Notably, autoantibody levels often accompanied anti-SARS-CoV-2 antibody concentrations, being both indicated by random forest classification as strong predictors of COVID-19 outcome, together with age. Moreover, higher levels of autoantibodies (mainly IgGs) were seen in the elderly with severe disease compared with young COVID-19 patients with severe disease. These findings suggest that the SARS-CoV-2 infection induces a broader loss of self-tolerance than previously thought, providing new ideas for therapeutic interventions.

Since the first case in December 2019, more than 395 million confirmed cases of the 25

Coronavirus disease 2019 (COVID-19), including 5,7 million deaths, were reported 1 . is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-27 stranded RNA virus that belongs to the Coronaviridae family 2 . Subsequently, new SARS-CoV-2 28 variants have kept on emerging, each presenting with selective advantages 3-5 and threatening the 29 possibility to dominate the COVID-19 pandemic 6 . Concurrently, a massive scientific endeavor to 30 understand COVID-19 pathophysiology has found evidence that patients with severe COVID-19 31 may present with systemic immune dysregulation of both the innate and adaptive immune 32

responses. This manifests mainly as cytokine storm syndrome 7 , hyperactivation of both myeloid 33 and lymphoid cells 7,8 , characterized by neutrophilia and lymphopenia) 9 . . In addition, recent 34 reports from our group and others 10,11,12 indicate that patients with COVID-19 have high levels of 35 autoantibody production, suggesting that SARS-CoV-2 can trigger features resembling systemic 36 autoimmune disease 13-17 . 37 In healthy individuals, autoantibodies are present at physiological levels regulating a 38 myriad of physiological functions, which are essential to maintain body homeostasis 18-21 . 39 However, abnormal levels of autoantibodies often predict preclinical autoimmune diseases 22 We employed random forest model to construct a classifier for discriminating controls and mild, 146 moderate, and severe COVID-19 patients. The aim of this approach was to identify the most 147 significant predictors for severe COVID-19. We trained the random forest model using the 148 functionalities of the R package randomForest (version 4.6.14) 65 . Five thousand trees were used, 149 and 3 variables were resampled. A follow-up analysis was conducted with the Gini decrease, the 150 number of nodes and mean minimum depth as criteria to determine variable importance. The 151 adequacy of the random forest model as a classifier was assessed through the out-of-bags error 152 rate and the ROC curve. For cross-validation, we split the dataset into training and testing sets, 153 using 75% of the observations for training and 25% for testing. 154 155

Bivariate correlation analyses of autoantibodies for each group (controls and mild, moderate and 157 severe COVID-19 patients) were performed using the corrgram, psych and inlmisc R packages. 158

In addition, circle plots of autoantibody correlation were built using the R packages qgraph, 159 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 18, 2022. ; ggplot2, psych, inlmisc to visualize the patterns of Spearman's rank correlation coefficients 160 between autoantibodies. 161 162

Progressive increase of autoantibodies in COVID-19 patients according to disease severity 164

Here we investigated the serum levels of IgG and IgA autoantibodies targeting 58 and 52 165 self-antigens, respectively, that are linked to a variety of autoimmune diseases (Fig. 1) We found significantly elevated levels of IgG (Supplementary Fig. 1 ) and IgA 175 ( Supplementary Fig. 2) autoantibodies targeting a total of 42 and 25 antigens, respectively, 176 when comparing COVID-19 groups (mild, moderate, and severe) versus healthy controls (Fig.  177   3a) . In general, while patients with mild COVID-19 exhibited only slight differences in the 178 serum levels of autoantibodies when compared to healthy controls, patients with moderate 179 COVID-19 exhibited more evident differences, with the highest levels of autoantibodies noted 180 in the severe group. In agreement with the results obtained by MSFA, we observed a progressive 181 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) increase of the autoantibodies targeting autoantigens such as those associated with Alzheimer's 182 disease (rabaptin-5, tau protein), antiphospholipid syndrome (cardiolipin), multiple sclerosis and 183 other neuroimmune disorders (myelin basic protein), celiac disease (transglutaminases, zonulin), 184 neuropsychiatric and neurodegenerative disorders (NMDAR), gut motility disorders (enteric 185 nerve), liver autoimmunity (liver microsomal antigen), immune thrombocytopenia (platelet 186 glycoprotein),myasthenia gravis (acetylcholine receptor, somatotropin), neurodegenerative 187 diseases (neurofilament proteins), Parkinson's disease (-synuclein), pemphigus vulgaris or 188 foliaceus (Desmoglein-E-Cadherin 1), neurological disorders (S100B), rheumatic heart disease 189 (-myosin), rheumatoid arthritis (-enolase, fibulin), systemic lupus erythematosus (cardiolipin, 190 dsDNA, rabaptin-5), type 1 diabetes (islet cell antigen), immune thrombotic thrombocytopenia 191 (heparin), and vitiligo (tyrosinase) (Supplementary Table 3, Supplementary Fig. 1-2 and Fig.  192 3a, 3d-e). In addition, we also identified reduced levels of IgG autoantibodies such as those 193 against a-myosin, rabaptin-5, S100B, and cerebellar as well as IgA autoantibodies targeting the 194 NMDA R and cerebellar. Thus, indicating a broad breakdown of physiological autoantibody 195 levels/self-tolerance in patients with COVID-19 that paralleled disease severity. Of note, the 196 progressive perturbation of autoantibody levels was accompanied by increased serum 197 concentration of anti-SARS-CoV-2 antibodies (Fig. 3e) . 198 Table 4  202 and Supplementary Fig. 3) . Taken together, our data indicate that autoantibodies may also be 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We then assessed whether anosmia (loss of smell), which was one of the most consistent 217 symptoms associated with SARS-CoV-2 infections 69 , also correlated with autoantibody 218 signatures in patients with mild or moderate COVID-19. Due to the extreme clinical condition 219 requiring oxygen replacement therapy that precludes the characterization of anosmia, patients 220 with severe COVID-19 were excluded from this analysis. We observed that the interconnections 221 among the autoantibodies are reduced in both mild and moderate COVID-19 with anosmia when 222 compared with those without (Supplementary Fig. 4e and Fig. 3b) . Taken together, this 223

suggests the presence of multilayered factors that influence the autoantibody signatures, 224 including both disease severity and anosmia that affect relationships among autoantibodies 225 differently. 226 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint

To investigate the classification power of autoantibodies, we used random forest modeling, 229 which predicts outcomes based on decision trees 70 , to rank the top 10 autoantibodypredictors of 230 COVID-19 outcomes. Random forest classification of COVID-19 patients presented a stable 231

curve showing the highest error rate (out-of-bag OOB) for the severe COVID-19 group based on 232 both IgA or IgG autoantibodies (Supplementary Fig. 6a, 6d, 6g, and 6h) . The confusion matrix 233

showed that the random forest model was unable to distinguish moderate from severe COVID-19 234 groups ( Supplementary Fig. 6b and 6e) . These results indicate that moderate and severe 235 COVID-19 patients may present a similar autoantibody signature. Therefore, we lumped 236 moderate and severe COVID-19 patients into the same group. Using this approach, the out-of-237 bag (OOB) estimate of the error rate for all groups changed from 37% to 22% for IgA (Fig. 5d ) 238 and from 25% to 12% for IgG autoantibodies (Fig. 5a) . This way, the model was considered 239 adequate to classify the COVID-19 patients by severity according to IgA and IgG autoantibodies, 240

showing areas under the ROC curve of 0.91%, 0.85%, and 0.90% for the healthy control, 241 moderate, and severe COVID-19 groups for IgA (Supplementary Fig. 6j ) and 0.98%. 0.96% 242 and 0.99% for IgG (Supplementary Fig. 6i) . In this context, autoantibodies tracked with anti-243 SARS-CoV-2 antibodies and age as predictive factors for COVID-19 outcome. Among them are 244

IgG autoantibodies targeting the NMDA R, insulin, PG, LSPC, human RO60, claudin, heparin, 245 and S100B, as well as IgA autoantibodies targeting cardiolipin, the NMDA R, HEK, cerebellar, 246 ICA, AbP, DEC, -synucleins, and tyrosinase. Thus, IgA and IgG autoantibodies stratify 247 COVID-19 according to disease severity. 248 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint

To better understand the stratification power of the autoantibody predictors of COVID-19 249 outcomes, we performed principal component analysis (PCA) with a spectral decomposition 250 approach 40,41 to analyze whether the top 10 ranked variables (IgA and IgG autoantibodies and 251 age) as predictors of COVID-19 severity have stratification power. This approach indicated, in 252 accordance with the random forest modeling, that the ranked autoantibodies stratify COVID-19 253 patients according to disease severity. (Fig. 5g and 5h ). While healthy controls and patients with 254 mild COVID-19 presented with similar autoantibody patterns, moderate and severe COVID-19 255 groups clustered closely. Together, these results indicate that the immune responses against 256 SARS-CoV-2 not only are associated with an increase of serum autoantibody levels linked to 257 autoimmune diseases, but also have predictive stratification values for COVID-19 patients. 258

Considering age as a major predictor of severe outcomes in COVID-19, which was also 261 identified by our data (Random forest) 71 , we investigated the effect of age on f the top IgG and 262

IgA autoantibody predictors of COVID-19 severity. We classified control and disease groups by 263 age (young < 60 and elderly ≥ 60) and found that both moderately and severely affected elderly 264 COVID-19 patients show an overall tendency to have elevated autoantibody levels when 265 compared with younger patients (Fig. 6a) . However, only elderly patients with severe COVID-266 19 presented with significant differences in most of the top 10 IgG (Fig. 6b) and IgA (Fig. 6c . 7a) . In turn, IgA autoantibodies against 10 antigens displayed significant differences 271 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint comparing young COVID-19 patients to severe COVID-19 patients (Supplementary Fig. 7b) . 272

No age-dependent differences were observed regarding the levels of anti-SARS-CoV-2 273 antibodies. 274

Of note, there were only a few (IgG autoantibodies targeting heparin and LSPC; SARS-275 CoV-2 antibodies; IgA autoantibodies targeting cardiolipin, DEC, ICA, and tyrosinase) age-276 dependent significant differences in patients with anosmia versus no anosmia regarding the top 277 10 autoantibody predictors of COVID-19 severity (Supplementary Fig. 8) . Furthermore, we 278 asked whether sex also impacts the levels of autoantibodies during SARS-Co-2 infections. IgG 279 anti-cardiolipin-aab was elevated in males from all three disease groups (but only significantly in 280 mild and moderate COVID-19 cohorts) when compared to females. Except for this, there were 281 no significant sex differences in the levels of the top 10 IgG and IgA autoantibody predictors of 282 COVID-19 severity (Supplementary Fig. 9) . receptor, rabaptin-5, somatotropin, S100B, tau protein, and transglutaminases 6) and non-293 neuronal antigens (e.g., -enolase, -myosin, claudin-5 and -7, collagen, desmoglein-E-cadherin 294 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. infection induces a broader loss of self-tolerance than previously thought, particularly in elderly 332 patients. In this context, several age-associated factors such as chronic inflammation in ageing 333 (inflammageing 86 ) might promote the production of autoantibodiesas well as the tendency to 334 naturally progress to immune dysregulation of innate 87 and adaptive 88 immune cells. Therefore, 335 our data support the idea that the induction of high levels of serum autoantibodies in elderly 336 COVID-19 patients contribute to the increased risk for negative outcomes in older persons 89 . 337

Because autoantibodies are strong predictors of COVID-19 severity, our findings expand 338 the number of autoantibodies that qualify as biomarkers for the severity of SARS-CoV-2 339 infection. Among them are those targeting molecules involved in neurological functions (e.g., 340

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint cognition, learning, memory, synaptic transmission) and glucose metabolism. For instance, while 341 anti-cardiolipin antibodies were previously associated with the development of 342 hyperinflammatory syndromes 90 , the high levels of autoantibodies targeting neuronal-associated 343 molecules could provide clues why the respiratory symptoms of COVID-19 patients are often 344 accompanied by short-and long-term neuropsychiatric symptoms and brain sequelae 68 . It has 345 been convincingly shown that SARS-CoV-2 is able enter the brain by crossing the blood-brain 346 barrier (BBB) because inflammatory cytokines induce BBB instability 68,91,92 . Our data indicate 347 that the array of autoantibodies targeting neuronal molecules is an additional molecular layer that 348 could contribute to the neurological manifestations 66,67 occuring in COVID-19 patients. 349

There are limitations of our worlk that need consideration. For instance, our study did not 350 have longitudinal data to analyze the pharmacokinetics of the IgG and IgA autoantibodies, from 351 disease onset to convalescence or post-acute COVID-19 syndrome. Our study cohort did not 352 include asymptomatic patients. Moreover, we cannot exclude the possibility that at least some of 353 our patients had high levels of autoantibodies prior to SARS-CoV-2 infection, or that 354 autoantibodies to some antigens (e.g., heparin) could have been induced by anticoagulant therapy 355 with heparin. In addition, we did not assess alterations in the number of circulating B 356 lymphocytes and whether this could explain the higher serum levels of autoantibodies. In CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ;

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity (which was not certified by peer review) Table 2 for full names and abbreviations of autoantibodies and their targets. All autoantibodies with significant differences between at least two groups are shown in Supplementary Figures 1 and 2 . Each box plot shows the median with first and third interquartile range (IQR), whiskers representing minimum and maximum values within IQR, and individual data points. Significance was determined using two-sided Wilcoxon rank-sum tests and is indicated by asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001). Control (n = 77); mild (n = 74), moderate (n = 65), and severe (n = 32) COVID-19. Fig. 4a-4d for correlograms with the autoantibody names; Supplementary Fig. 4e for IgG autoantibody correlations in patients with anosmia versus no anosmia; and Supplementary Fig.  5 a-b for IgG and IgA autoantibodiy correlations for healthy controls and COVID-19 groups. The color scale bar ranging from 0 to 1 represents Spearman's rank correlation coefficient. Rows and columns were clustered based on Euclidean distance. See Supplementary Table 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint for correlations matrices with the correlation coefficient values. Control (n = 77); mild (n = 74), moderate (n = 65), and severe (n = 32) COVID-19. No anosmia (n = 69) and anosmia (n = 101).

showing number of trees and error rates for a) IgG and d) IgA autoantibodies with out-of-bag (OOB) estimate of 12,5% and 22.28% error rate, respectively. Heatmap presents the confusion matrix of b) IgG and e) IgA autoantibodies, the number of individuals classification by group (healthy controls = G1; mild = G2; moderate+severe = G3). The color scale ranging from blue to orange corresponds to the number of errors or hits by groups denoted inside the colored or white squares, respectively. Control (n = 77); mild (n = 74), moderate+severe (n = 97) COVID-19. Bar plots of the top 10 strongest c) IgG (also anti-SARS-CoV-2 IgG antibodies and age) and f) IgA autoantibodies predictors of COVID-19 patient classification according to disease severity. The variables are shown according to minimal depth and number of trees. The color scale bar ranging from 0 to 13 represents the minimal and maximum minimal depth. The small dark vertical bars represent the mean of minimal depth for each variable. Principal component analysis (PCA) with spectral decomposition shows that g) IgG and h) IgA autoantibodies stratify COVID-19 patients according to disease severity, revealing the overlap between the moderate and severe cohorts. The PCA was carried out based on the top 10 most important variables as listed in c and f, respectively. Control (n = 77); mild (n = 74), moderate (n = 65), and severe (n = 32) COVID-19. See Supplementary Table 2 for full names and abbreviations of autoantibodies and their targets. The colors blue and light yellow indicate autoantibodies with or without significant differences between the young versus elderly in each group. b) Box plots display changes in the autoantibody levels by age (young < 60 and elderly ≥ 60). Each box plot shows the median with first and third interquartile range (IQR), whiskers representing minimum and maximum values within IQR, and individual data points. Significance was determined using two-sided Wilcoxon rank-sum tests and is indicated by asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001). control-young (n = 65) and control-elderly (n = 12); mildyoung (n = 70), mild-elderly (n = 4), moderate-young (n = 45), moderate-elderly (n = 20), severe-young (n = 20), severe-elderly (n = 12) COVID-19 patients. All autoantibodies with significant differences between at least two groups are shown in Supplementary Fig. 7 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.17.22271057 doi: medRxiv preprint

Losartan for Patients With COVID-19 Requiring Hospitalization -Full Text View -496 ClinicalTrials.gov. 497 44. Cavalli, E. et al. Entangling COVID-19 associated thrombosis into a secondary 498 antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives

Autoimmune and inflammatory diseases following COVID-19

Systemic and organ-specific immune-503 related manifestations of COVID-19

Association of Varying Clinical Manifestations and Positive Anti-505 SARS-CoV-2 IgG Antibodies: A Cross-Sectional Observational Study

SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked 508 Orthodox Jewish Communities Across Multiple Regions in the United States

COVID-19 Clinical management: living guidance

Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-512

Subunit Induces Experimental Myasthenia Gravis in Rats

Antibodies against Group A Streptococcus, dopamine 515 receptors, and ganglioside GM1 cross-react with a variety of food antigens, potentially 516 interfering with biomarkers for PANS and PANDAS

Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: 520 Implications in Human Disease

Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in 522 Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42

Multi-study Factor Analysis

Points of Significance: Principal component 545 analysis

What is principal component analysis?

IID 2021: towards context-specific protein interaction analyses by 549 increased coverage, enhanced annotation and enrichment analysis

) (PDF) Classification and Regression by RandomForest

Assessment of Cognitive Function in Patients After

Impact of SARS-CoV-2 Infection on Cognitive Function: A 555 Systematic Review. Front

How COVID-19 Affects the Brain

Anosmia, ageusia, and other COVID-19-like symptoms in association 559 with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an 560 observational study

Classification and Regression by randomForest

SARS-CoV-2, COVID-19 and the aging immune system

Prevalence of autoantibody responses in acute coronavirus disease 565 2019 (COVID-19)

Autoantibodies against human epithelial cells and endothelial cells after 567 severe acute respiratory syndrome (SARS)-associated coronavirus infection

Cerebral arterial and 570 venous thrombosis due to COVID-19 vaccine-induced immune thrombotic 571 thrombocytopenia

Prevalence of autoantibody responses in acute coronavirus disease 573 2019 (COVID-19)

Cabral-Marques, O. & Riemekasten, G. Functional autoantibodies targeting G protein-577 coupled receptors in rheumatic diseases

Anti-cytokine autoantibodies are ubiquitous in healthy individuals

Molecular mimicry and autoimmunity

Epitope spreading: protection from pathogens, but 584 propagation of autoimmunity?

Post-acute COVID-19 associated with evidence of bystander T-cell 586 activation and a recurring antibiotic-resistant bacterial pneumonia

SARS-CoV-2 Proteome Harbors Peptides Which Are Able to 588 Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population 589 Coverage

Reaction of Human Monoclonal Antibodies to 591 SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases

Potential antigenic cross-reactivity between SARS-CoV-2 594 and human tissue with a possible link to an increase in autoimmune diseases

Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19

Inflammageing: chronic inflammation in ageing, cardiovascular 599 disease, and frailty

Age-dependent dysregulation of 601 innate immunity

The Complex Role 603 of Regulatory T Cells in Immunity and Aging

Association of Age With Likelihood of Developing Symptoms and 605 Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-606 2 Infection in Italy

Correlation Analysis of Anti-Cardiolipin Antibody/D

Dimer/C-Reactive Protein and Coronary Artery Lesions/Multiple-Organ Damage in 609

SARS-CoV-2 crosses the blood-brain barrier accompanied with basement 611 membrane disruption without tight junctions alteration

The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice

COVID-19 and autoimmune diseases

The intersection of COVID-19 and autoimmunity

COVID-19 and Autoimmune Diseases: A Systematic Review of 620 Reported Cases

Cardiolipin-aab Claudin-5-aab Heparin-aab Human RO60-aab Insulin-aab α-Synucleins-aab AbP-aab Cardiolipin-aab Cerebellar-aab HEK-aab DEC-aab ICA-aab NMDA R-aab Tyrosinase-aab